Literature DB >> 19352469

Accomplishments in 2007 in the management of advanced gastroesophageal cancer.

Jaffer A Ajani1, Hans-Joachim Schmoll.   

Abstract

Overview of the Disease Process IncidencePrognostic or Predictive FactorsCurrent General Therapy Standards Regional VariationsEvidence for Individual AgentsAccomplishments During the Year TherapyBiomarkersBasic ScienceWhat Needs To Be Done Applications of the AccomplishmentsControversies and DisagreementsSpecial PopulationsFuture Directions Comments on ResearchObstacles to Progress.

Entities:  

Year:  2008        PMID： 19352469      PMCID： PMC2664914     

Source DB:  PubMed          Journal:  Gastrointest Cancer Res        ISSN： 1934-7820


  11 in total

1.  The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence.

Authors:  Heiko Pohl; H Gilbert Welch
Journal:  J Natl Cancer Inst       Date:  2005-01-19       Impact factor: 13.506

2.  Global cancer statistics, 2002.

Authors:  D Max Parkin; Freddie Bray; J Ferlay; Paola Pisani
Journal:  CA Cancer J Clin       Date:  2005 Mar-Apr       Impact factor: 508.702

3.  Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.

Authors:  Eric Van Cutsem; Vladimir M Moiseyenko; Sergei Tjulandin; Alejandro Majlis; Manuel Constenla; Corrado Boni; Adriano Rodrigues; Miguel Fodor; Yee Chao; Edouard Voznyi; Marie-Laure Risse; Jaffer A Ajani
Journal:  J Clin Oncol       Date:  2006-11-01       Impact factor: 44.544

4.  Outcome of gastric cancer patients after successful gastrectomy: influence of the type of recurrence and histology on survival.

Authors:  Pooja R Rohatgi; James C Yao; Kenneth Hess; Isac Schnirer; Asif Rashid; Paul F Mansfield; Peter W Pisters; Jaffer A Ajani
Journal:  Cancer       Date:  2006-12-01       Impact factor: 6.860

5.  S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial.

Authors:  Wasaburo Koizumi; Hiroyuki Narahara; Takuo Hara; Akinori Takagane; Toshikazu Akiya; Masakazu Takagi; Kosei Miyashita; Takashi Nishizaki; Osamu Kobayashi; Wataru Takiyama; Yasushi Toh; Takashi Nagaie; Seiichi Takagi; Yoshitaka Yamamura; Kimihiko Yanaoka; Hiroyuki Orita; Masahiro Takeuchi
Journal:  Lancet Oncol       Date:  2008-02-20       Impact factor: 41.316

6.  Cancer statistics, 2008.

Authors:  Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Yongping Hao; Jiaquan Xu; Taylor Murray; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2008-02-20       Impact factor: 508.702

7.  Effect of timing of metastasis/disease recurrence and histologic differentiation on survival of patients with advanced gastric cancer.

Authors:  Pooja R Patel; James C Yao; Kenneth Hess; Isac Schnirer; Asif Rashid; Jaffer A Ajani
Journal:  Cancer       Date:  2007-11-15       Impact factor: 6.860

Review 8.  Optimizing docetaxel chemotherapy in patients with cancer of the gastric and gastroesophageal junction: evolution of the docetaxel, cisplatin, and 5-fluorouracil regimen.

Authors:  Jaffer A Ajani
Journal:  Cancer       Date:  2008-09-01       Impact factor: 6.860

9.  Capecitabine and oxaliplatin for advanced esophagogastric cancer.

Authors:  David Cunningham; Naureen Starling; Sheela Rao; Timothy Iveson; Marianne Nicolson; Fareeda Coxon; Gary Middleton; Francis Daniel; Jacqueline Oates; Andrew Richard Norman
Journal:  N Engl J Med       Date:  2008-01-03       Impact factor: 91.245

10.  Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.

Authors:  Shinichi Sakuramoto; Mitsuru Sasako; Toshiharu Yamaguchi; Taira Kinoshita; Masashi Fujii; Atsushi Nashimoto; Hiroshi Furukawa; Toshifusa Nakajima; Yasuo Ohashi; Hiroshi Imamura; Masayuki Higashino; Yoshitaka Yamamura; Akira Kurita; Kuniyoshi Arai
Journal:  N Engl J Med       Date:  2007-11-01       Impact factor: 91.245
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.